key: cord-0792244-b9ix13d1
authors: Ng, Alexander Clevewood
title: Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use
date: 2021-06-22
journal: Hepatol Commun
DOI: 10.1002/hep4.1750
sha: 8e2a123ce9c28a23efab6dbfda04585c2ef09a40
doc_id: 792244
cord_uid: b9ix13d1

nan

Also, patients with non-AIH CLD might be treated with immunosuppressive agents (e.g., steroids) to avoid hyperinflammation in severe COVID-19. Most patients with AIH also maintained immunosuppressive therapy during COVID-19 (62.7%). Thus, the nonsignificant difference in survival outcomes between the two groups can be explained by the attainment of similar levels of immunosuppression during COVID-19.

Secondly, tacrolimus can potentially be used for immunosuppression in patients with AIH with COVID-19. AIH is largely treated by corticosteroids and azathioprine. In a real-world-experience study, over half of patients with AIH who used calcineurin inhibitor as second-line/third-line therapy (due to azathioprine/steroid intolerance or incomplete response) achieved normalization of serum aminotransferases. (6) Because tacrolimus shows protection against COVID-19, its use in patients with AIH might be encouraged. Unfortunately, only 5 patients in this study used tacrolimus (none used tacrolimus monotherapy). More studies are required to analyze the clinical relevance of tacrolimus in patients with AIH with COVID-19.

Outcome of COVID-19 in patients with autoimmune hepatitis: an international multi-centre study

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Members and Collaborators of ERN RARE-LIVER/ COVID-Hep/SECURE-Cirrhosis. SARS-CoV-2 infection in patients with autoimmune hepatitis

Fibrosis and alcohol-related liver disease

Determinants of fibrosis progression and regression in NASH

Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience